GENFIT

AGM Information • Feb 26, 2014

www.genfit.com

GENFIT TO HOLD A COMBINED GENERAL SHAREHOLDERS' MEETING ON APRIL 2, 2014

Lille (France), Boston (Massachusetts, United States), February 26, 2014 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces that it will hold a Combined General Shareholders' Meeting ("the Meeting") on April 2, 2014 at 10:30 a.m., at the Company's headquarters, situated at 885 avenue Eugène Avinée, 59120 Loos, France.

The Meeting announcement published today in the BALO (French Gazette of Obligatory Legal Announcements) contains the agenda, the text of the proposed resolutions, and the formalities regarding attendance and voting rights. The announcement may also be consulted on the company's web-site at the following address: http://genfit.com/en/investisseurs/rapports-financiers/index.html

All documentation concerning the Meeting will be made available to shareholders under the conditions and within the timeframe specified by current regulations, and may be consulted on the Company's web-site. The Executive Board report, describing in particular the context and the objectives of the Meeting, is already available on the Company's website, at the following address: http://genfit.com/en/investisseurs/rapportsfinanciers/index.html

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT Jean-François Mouney – CEO & Chairman of the Management Board Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian Ph. +331 7544 8740 / +336 8788 4726 – barabian@milestones.fr